Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07481604 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Sponsor changed: CHA Vaccine Institute Co., Ltd. to Aribio Lab Co., Ltd.
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.
Trial Details
NCT Number NCT07481604
Lead Sponsor Aribio Lab Co., Ltd.
Conditions
(from sponsor)		 Herpes Zoster
Related terms Chickenpox, Herpes Zoster
Enrollment 135 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov